Postagem em destaque

CRISPR crunch

Genetic engineering CRISPR crunch A row over who invented a new gene-editing technique heats up Feb 20th 2016  |  WASHINGTON, DC  |...

quarta-feira, 30 de setembro de 2015

Australian Goverment - Innovation Patent

An innovation patent lasts up to 8 years and is designed to protect inventions that do not meet the inventive threshold required forstandard patents. It is a relatively quick and inexpensive way to obtain protection for your new device, substance, method or process.
An innovation patent is usually granted within a month of filing the complete application. This is because there is no examination before it is granted.
The innovation patent requires an innovative step rather than an inventive step, to protect an incremental advance on existing technology that may not qualify for standard patent protection rather than a groundbreaking invention.
An innovative step exists when the invention is different from what is known before and the difference makes a substantial contribution to the working of the invention.
If you want protection for an invention with a short market life that might be superseded by newer innovations, such as computer based inventions, an innovation patent is worth considering.
Important: Examination of an innovation patent will only occur if requested by the patentee, a third party or if the Commissioner of Patents decides to examine the patent. An innovation patent is only legally enforceable if it has been examined by us, been found to meet the requirements of the Patents Act, and  has been certified.

Benefits of the innovation patent

  • If it is examined and certified, the innovation patent offers the same level of protection as a standard patent in preventing others from copying your invention.
  • Unlike a standard patent, you only pay to have an innovation patent examined when you need to stop others from copying your invention.

Limitations of the innovation patent

The innovation patent is granted without examination, which means validity of the application is not verified by us. This may make the patent more difficult to sell or license until the patent has been examined and certified.
Also, you are unable to go to court to enforce the innovation patent until it has been examined and certified.
An innovation patent can only be applied for in Australia. You have to apply separately in other countries if you want to enforce the patents overseas. 

Comments:
I think it is goog to understand about these things. In Brazil, I agree that we have work hard. Our laws should have change... I always asking - Why Brazil cannot be a world potention economy? Why are we so distance to other countries? Why? And Why?

segunda-feira, 28 de setembro de 2015

Do you know about MIRA's Project? MIRA - Mediterranean



Perfect project people! I think that they make difference in innovation!




Learning more:

The Mediterranean Innovation and Research Action (MIRA) is an INCO-Net Coordination Action financed by the International Cooperation - Capacities Program of the 7th Framework Program of the European Union.
It aims at developing a scientific and technological partnership between the European Union (EU) and the Mediterranean Partner Countries (MPC), by the use of dialogue platforms, identifying topics of common scientific interest, promoting the creation of an Observatory of EU-MPC scientific cooperation, and promoting the development of the Euro-Mediterranean Innovation Space and other join initiatives with a research component such as the Horizon2020 Program of de-contamination of the Mediterranean. Moreover, it support to the functioning of the Monitoring Committee for Euro-Mediterranean Cooperation in S&T (MoCo).

Most innovative companies 2014 in United Kigton

THE TOP 10 MOST INNOVATIVE COMPANIES IN THE U.K.

BRITISH INNOVATION IS GOING STRONG AS EVER.

1. DYSON

For advancing everyday tools to the point of perfection. Engineer James Dyson's bagless vacuums and bladeless fans have made innovation a household word in the U.K. Today, 85% of Dyson machines are sold to global markets, up from 30% in 2007. The company invests more than $2 million weekly in research and development, yielding such products as the recent Airblade Tap: a 10-second digital, motor-powered water faucet that both washes and dries (using 450-mph wind).

2. SHAZAM

For plunging into the always-on feature future. Shazam is like Pop Up Video for everyday life: Press a button and the app IDs any song, TV show, movie, or ad you hear. Its CEO, Rich Riley, believes we've reached a new smartphone era: "The world is going to an always-on state for apps," he says. In December, Shazam showed what that looks like with Auto Shazam, an opt-in feature that quietly keeps a diary of your day's playlist for you. In its first month, Auto Shazam logged 1 million daily recognitions. With 350 million users worldwide—and with the company adding 10 million more per month—there's plenty of room to grow. Read more >>

3. MIND CANDY

For creating entertainment for a new generation. Winning the hearts of 80 million children, Mind Candy's online phenomenon Moshi Monsters allows kids to adopt their own virtual pet. The franchise now includes books, magazines, TV shows, and toys, all of which fuel its $45 million in revenue. Founder Michael Acton Smith, who recently launched an innovation center called Candy Labs, uses the online space as a testing ground to build strong, character-based games and apps before taking the products offline. The company's first animated film, Moshi Monsters: The Movie, hit U.K. and Ireland theaters in December with the help of production partner Universal Studios.

4. ARM HOLDINGS

For putting the smarts in 95% of the world's smart devices. The Cambridge-based ARM designs low-energy, high-performance microprocessors that are embedded in most of our smartphones and tablets. Its 64-bit chips power the hit iPhone 5s, and ARM is now ramping up semiconductor production for the surging market for the Internet of Things. That means the company—which will now have thermostats, fridges, and washing machines to toy with—will expand its reach further into our daily (digital) lives.

5. SPOTIFY

For validating the streaming-music business by putting artists first. Headquartered in London and Stockholm, Spotify's quest to stabilize the still-shaky music industry is paying off, both for artists and for the company. Thanks in part to new features that make it easier for listeners to discover music (and concerts), Spotify has grown to nearly 26 million active users—6 million of whom pay $10 for ad-free access. The company claims to pay out nearly 70% of its revenue in royalties (nearly $500 million in 2013), which has drawn skepticism to its business model. Spotify, however, has been partly credited with lifting music revenues in Sweden by 5%, and earlier this year, it was able to drop its time limit for free web listening—proof that its formula is working. Even the mighty Apple is chasing Spotify's success with the monochrome iTunes Radio.

6. BURBERRY

For fashioning a tech revolution in traditional British retailing. With annual sales of more than $3 billion, the 1856 luxury brand is an object lesson in leveraging digital media, with live-streamed runway shows and whimsical online marketing initiatives like Burberry Kisses, plus a high-tech Regent Street Burberry flagship that brings its online trench coat customization site to life. The company credits digital investment and online sales for a 14% uptick in revenue at the end of last year.

7. HEATHERWICK STUDIO

For achieving groundbreaking design in one of the world's oldest cities. Thomas Heatherwick has been likened to a modern-day Leonardo da Vinci: His London-based design practice, Heatherwick Studio, employs 110 architects, industrial designers, and model makers. The studio's recent projects include the 2012 Olympic cauldron, a revamped double-decker bus, a Bombay Sapphire gin distillery, and plans for a pedestrian Garden Bridge across the River Thames, replete with wildflowers, grass, and trees.

8. RASPBERRY PI FOUNDATION

For hacking together a $25 credit card–size programmable computer. The Raspberry Pi computer came out of the University of Cambridge to help teach the world's kids to program with a tiny, accessible machine that plugs into a TV and keyboard. Now a registered charity, Raspberry Pi allows anyone to build and prototype new products quickly and cheaply. Scrappy Raspberry Pi–enabled programmers have already used the technology to build everything from baby monitors to weather stations and robots.

9. BERG

For inventing quirky, cloud-powered products. London-based design consultancy Berg is responsible for whimsical gadgets like the Little Printer, which prints out a custom newspaper from web-sourced content, and a recent prototype of a tweet-powered cuckoo clock (in collaboration with Twitter UK, of course). The company recently partnered with Treviso, Italy–based Fabrica to launch Sandbox, a collaborative research and development program. Based on the company's Cloud platform, the initiative aims to help academics and businesses create products and services for the Internet of Things.

10. MARKS & SPENCER

For pruning its sprawling stores into greener, leaner machines. Marks & Spencer has taken a systemic approach to sustainability, resulting in a 23% decrease in CO2 emissions since 2007, zero waste to landfill, and carbon-neutral stores, warehouses, offices, and delivery fleets in the UK. With web and mobile sales up nearly 17%, the $15 billion traditional British retailer is refocusing its resources on building an international multichannel brand with a popular new mobile app and a London-based digital lab.

Published by:

It's so amazing think about it ... Grow human teeth from Urine ... Oh my God! =)

Chinese Scientists Grow Human Teeth from Urine

Chinese Scientists Grow Human Teeth from Urine
China is making significant progress in the field of 
stem cell research
Last month Chinese scientists announced that they have succeeded in growing rudimentary teeth using stem cells. The results, published in Cell Regeneration Journal, showed that human urine could be used as a source of stem cells that in turn could be grown into tiny tooth-like structures.
The scientists from the Guangzhou Institute of Biomedicine and Health hope the technique could be developed into a way of replacing lost teeth.
How they did it was taking human stem cells obtained from human urine and combined them with tissue from a mouse jaw taken from a mouse embryo. As stem cells can take on the form of whatever body part they’re implanted into, the scientists hoped the human stem cells would produce human tissue. And since it was implanted into a mouse jaw, they gambled that the item grown would be a tooth. And they were right on both hypotheses. Once the human stem cells were successfully implanted into the mouse jaw material, the tiny package was then implanted into the kidneys of live mice. It took the stem cells and jaw material only three weeks to grow into a human tooth-like structure. The stem cells had developed into a cyst. And inside each cyst was a small tooth.
The researchers admit that their success rate was only 30%. But they were more than encouraged by their results. The teeth they grew were as hard as human teeth and could even be grown to specific sizes and shapes to create the right replacement tooth for future dental patients.
This innovative example shows that China is making significant progress in the field of stem cell research.
Chinese Scientists Grow Human Teeth from Urine
© Cell Regeneration Journal – Scientists turned urine stem cells into teeth.

An Overview of China’s Tech & Startup Ecosystem

by  on 


Last week we came across a very insightful slideshow titled “Technopreneurship and the Early Stage Ecosystem in China”. This presentation has been recently created by Chris Evdemon, a partner atInnovation Works (one of China’s leading VC firms).
If you want to read a great summary on China’s current Internet landscape you really should take half an hour to watch these slides.
Some interesting take-aways:

  • Mobile internet is increasing exponentially in China and therefore accelerates everything. Android is by far the leading mobile OS in China and Chris points out that Android will be at the core of China’s next few multi-billion dollar companies.
  • He indicates 4 steps for Chinese innovation.
  • The freemium model rules in China and the West can learn a lot from it. Almost all apps are free to download in China and developers monetize via in-app purchase or ads.
  • China’s startup ecosystem is immature and startup services are relatively scarce.
  • He provides an overview of strategic investments and M&A by the Big Three (Tencent, Alibaba and Baidu)*.


To see the Power Point - click here:


This site is too exciting! =)

I love how China grows economically... I agree that Brazil is the country that can get there like China.  But ... We have to working hard for it. Kisses people!

Mayara Rezende
Manager

sábado, 26 de setembro de 2015

3-D Printing’s Next Act: Nerve Regeneration

 Researchers demonstrate customized implants that help injured nerves regenerate in rats.

Bridging the gap between the ends of a torn nerve is the latest biomedical trick performed with the help of a 3-D printer.

Additive manufacturing, or 3-D printing, makes it possible to build more customized biomedical implants, and has become a popular way to make dental implants and even windpipes. A new 3-D printed structure meant to “guide” the regrowth and reconnection of the loose ends of an injured nerve suggests that the technique could appeal to neurosurgeons as well.

Peripheral nerve injuries, caused by a variety of things including disease and trauma, are fairly common—doctors perform more than 200,000 nerve repair procedures each year in the United States alone. The most common surgery entails using nerve tissue taken from another spot in the body to fill the gap. But this requires an additional surgery to harvest that tissue, and can lead to chronic pain, sensory loss, or other problems at the site from which it was cut. An alternative approach involves using an artificial scaffold, generally tube-shaped, that sits between the two ends of the broken nerve and serves as a conduit for regeneration, often with the help of biochemical cues known to prompt nerve growth.

But nerves and nerve injuries are often not so straightforward, and 3-D printing technology makes it possible to design and make guides that are conducive to more complicated shapes, says Michael McAlpine, a professor of mechanical engineering at the University of Minnesota. To demonstrate the new technique, McAlpine and his collaborators, including neurosurgeons and biomedical engineers, showed in rats that they could regenerate the original Y-shaped structure after a 10-millimeter piece of the sciatic nerve—including the point where it branches—had been cut out.
The researchers used a 3-D scanner to record information about the geometry of the missing piece, and fed that data into their custom printer. In an intact and functioning sciatic nerve, the base of the Y shape contains a mix of motor and sensory nerve fibers. It splits into branches that contain either mostly sensory nerve fibers, which send information to the brain, or mostly motor neurons, which send information to the muscles. On the inside of the silicone guide, the same printer deposits precise amounts of biochemical “cues” chosen to promote nerve growth. Each branch of the Y shape gets a different cue—one is meant to encourage sensory nerve growth and the other is meant to encourage the growth of motor nerves.
If the technology is to eventually advance to the clinic, it will not be essential that the missing piece of an injured nerve be available for 3-D scanning, says McAlpine, which is important because many injuries likely won’t afford that luxury. In that case, a corresponding nerve on the opposite side of the body may be able to stand in for scanning, he says, or perhaps there could even be existing “libraries” of geometrical data based on nerves from cadaver models.
The new technique should be thought of as a starting point that “opens the door” for the development of new regeneration schemes that take advantage of 3-D printing to make implants with complex shapes, says Xiaofeng Jia, a collaborator on the project and a professor of neurosurgery at the University of Maryland School of Medicine. It should be possible to use this approach to create more complicated branching designs suited for other nerves, he says, and it’s also possible that alternative materials and biochemical schemes will be more effective at promoting the healing of injured nerves.
McAlpine says the group will continue to experiment with different materials, and in particular he’d like to try to use a biodegradable material that would dissolve in the body once it has served its function. He estimates that the technology could be ready for testing in humans in five to 10 years.
Published by:

domingo, 20 de setembro de 2015

WTO Review Finds Brazil Progressing On Trade Policy, IP Rights Protection

Brazil, once criticised for lax intellectual property rights protection, has been stepping up implementation and enforcement of international IP rules in recent years, a World Trade Organization body announced Wednesday. But some major rights-holding nations urged the government to undertake further work.

Brazil came out with “flying colours” in a recent review of its trade policies over the last four years, said the president of the WTO body that conducted it. The country is increasing wealth as well as distributing it in a more equitable way, said WTO Trade Policy Review Chair Ambassador Istvan Major, of Hungary. Trade policy reviews of WTO members are conducted periodically and consist of both the WTO secretariat review of a country’s trade policies and the countries’ reports on their own policies.
Brazil also is expected to navigate the financial crisis better than many other global economies, and already is faring better than many developed countries, said another member of the review mechanism at an 11 March press conference on the trade policy review.
Intellectual property policies were a notable area of progress in the 2004 – 2007 period of review, the official said, as there was new legislation adopted and clear changes in it IP law.
Recent areas of interest in IP in Brazil – notably, the controversy over a stopped shipment of generic hypertension medicines from India by the Netherlands – were not mentioned in the report, as they are too recent, according to one of the secretariat members.
Major areas of progress were on a new “comprehensive and modern IP protection law” and on improved enforcement of obligations under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, said Major, though on the latter they were “invited to make further efforts.”
The country complies with all major aspects of the TRIPS agreement, and grants rights in excess of the minimum requirement in areas such as copyright law and pipeline patents, the WTO secretariat report on the review said.
The Brazilian government report said that in 2004 it established a National Council to Combat Piracy and Crimes against Intellectual Property, an equal partnership between government representatives and private sector representatives. The Brazilian Association of Software Companies gave the partnership an award in 2007 for the decline of software piracy from 64 to 60 percent in a year.
Legislation adopted in 2007 on layout designs of integrated circuits also was a significant change, a separate official from the WTO secretariat told reporters. Integrated circuits, or silicon chips, are essential to most modern electronics, including computers and mobile telephones. Previously, the designs of these circuits had no specific law in Brazil under which they were protected.
The secretariat’s report said the number of patents granted annually has declined since 2003, from 4,725 in 2003 to 1,855 in 2007. The report says timely patent processing is still an issue: the average time a patent spends waiting for approval is seven years.
Registrations of industrial designs also declined, from 5,651 in 2003 to 4,085 in 2007, though trademark registrations increased, from 10,541 in 2003 to 128,540 in 2007.
Other changes since the last review include guidelines and regulations for genetically modified organisms, and the introduction in 2006 of a 10 percent preference margin for small and medium-sized enterprises competing for government procurement contracts. Brazil is not a member of the WTO Government Procurement Agreement. It was invited to join, but indicated that “for the time being it is not in the cards,” reported Major.
This concerned the United States, which said in a statement it was “concerned with Brazil’s non-transparent policies on government procurement as well as lack of participation in the WTO GPA.” The US agreed with the WTO secretariat and encouraged Brazil to “consider the benefits of joining,” the statement added. The European Union echoed this encouragement.
One compulsory licence was issued on an HIV/AIDS medication, in May 2007. The decision allowed Brazil to import or manufacture generic versions of the drug, efavirenz. A compulsory licence is an exception to patent law. Under TRIPS, there is public health flexibility for governments to allow the manufacture of generic versions of medicines under patent without permission of the patent holder.
The United States recognised Brazil’s progress on IP “particularly with respect to pirated audiovisual goods” but said that stronger IP enforcement legislation is needed on book and internet piracy. The US also asked that Brazil look into acceding to the World Intellectual Property Organization “internet treaties,” covering copyright and performances online.
The European Union also called for increased enforcement, and mentioned the “general backlog” of patents and trademark applications.
Brazil is a net importer of IP: importing US$2.25 billion in royalties and licence fees, and exporting US$319 million, said the WTO secretariat report.
Brazil also received commendation for its role in the Doha Round of trade liberalisation negotiations, said Major. The current round of talks was launched in Doha, Qatar in 2001.
The Doha Development Round, said the Brazilian report, “will only be successful if it results in benefits for all members, particularly for developing countries.”


- Can we change this history? Can Brasil goes to top of economic status?
I think we can. I believe that Brazil is a country that can increased it economy with the all diversity that its has.... So, you may say "I'm dreamer" but I'm not the only one.... Like John Lennon's song...

sexta-feira, 18 de setembro de 2015

Brazilian Biodiversity – Opportunities for innovation - Good news for us!



Published by:

http://biominas.org.br/en/blog/2015/07/07/2800new-brazilian-law-on-biodiversity/

Contact

Hello!

Friends, if you have suggestions, criticism or praise , contact us : 


 Send an e- mail: rezendema@hotmail.com 

or

On Facebook:

https://www.facebook.com/mayara.rezende.9




Your opinion are important to support the blog!

Thank you!

Mayara Rezende
Manager

Important - Negligency Diseases

R&D plan announced for drugs for neglected diseases


By the Pharmaceutical Journal

The Drugs for Neglected Diseases initiative, a non-profit research and development organisation, has announced that it aims to spend €650m over the next eight years to deliver 16–18 treatments for up to ten diseases.
It will continue to prioritise leishmaniasis, African sleeping sickness, Chagas disease, paediatric HIV and filarial infections. It will also launch new research and development projects for hepatitis C and mycetoma in a bid to try and deliver safe and effective quality products that are affordable to poor populations.

“DNDi will remain focused on reaching treatment targets for the most neglected diseases, but we are now in a position to apply news R&D models, where patient needs drive drug development over profits, and where prices of drugs are delinked from the cost of their development,” says Bernard Pécoul, DNDi executive director.
The group, which works in partnership with industry, public institutions, academia and non-governmental organisations, says the high cost of new drugs “has become one of the world’s most pressing and high-profile public challenges, leaving millions of patients behind”.
In its pursuit of an affordable hepatitis C drug, DNDi says it will conduct clinical trials for drug combinations consisting of recently approved therapies and clinical stage compounds in middle-income countries.
DNDi has made six treatments available since its inception in 2003, including two fixed-dose antimalaria combination therapies (ASAQ and ASMQ), nifurtimox-eflornithine combination therapy for late-stage sleeping sickness, sodium stibogluconate and paromomycin combination therapy for visceral leishmaniasis in Africa, and a paediatric dosage form of benznidazole for Chagas disease.

Published by: The Pharmaceutical JournalURI: 20069358






terça-feira, 15 de setembro de 2015

Pfizer loses Lyrica patent infringement case

Pfizer loses Lyrica patent infringement case

Lyrica manufacturer loses battle to protect second medical use patent.
Pfizer has lost its patent infringement case against generic drug manufacturers Actavis and Mylan over the use of pregabalin, which Pfizer markets as Lyrica. In the image, package of Pfizer's Lyrica
Source: Barry Mason / Alamy Stock Photo
Pfizer intends to appeal the High Court ruling on Lyrica’s second medical use patent
Pfizer has lost its patent infringement case against generic drug manufacturers Actavis and Mylan over the use of pregabalin, marketed as Lyrica.
The High Court ruling on 10 September 2015 means that doctors can continue to prescribe the drug generically and pharmacists can dispense generic pregabalin without fear of patent infringement litigation.
Pfizer developed Lyrica for the treatment of generalised anxiety disorder (GAD) and epilepsy but the patent for this indication expired in 2013. When Pfizer discovered that pregabalin could relieve pain, it took out a second medical use patent for Lyrica to cover this use. When the first patent expired, Actavis and Mylan launched generic versions of the drug to treat GAD and epilepsy.
However, since UK physicians tend to prescribe generically, in December 2014 Pfizer claimed that its second medical use patent was being breached. But Mr Justice Arnold ruled that six claims of the patent were invalid on the ground of insufficiency; and that “Pfizer is liable for making groundless threats of patent infringement proceedings, albeit not in all the cases alleged by Actavis”.
Announcing its intention to appeal the ruling, Pfizer says it maintains its “strong belief in the validity, and importance, of the second medical use patent for the use of Lyrica in pain”.
A spokesperson for the Pharmaceutical Services Negotiating Committee, the negotiating body for pharmacy contractors in England, says the judgement will come as a relief to contractors. “It confirms that pharmacists were not in breach in this case,” the spokesperson says. “Pharmacists may now freely dispense generic pregabalin where the prescription is written generically. Where a prescription is written for a particular brand, then the pharmacist must, as usual, provide that brand.
“If a similar case arises again we hope the government will issue timely and clear guidance to pharmacies and prescribers.”
Pfizer had earlier been buoyed in its battle to protect Lyrica’s secondary patent when a judge ordered NHS England to issue guidance to doctors asking them to use the brand name Lyrica when prescribing the drug for pain. Pharmacists were also asked to dispense the branded version of the drug when they had been told the indication was for pain “so far as reasonably possible”.
Berkeley Phillips, Pfizer’s medical director in the UK, says protection of second medical use patents recognises the importance of ensuring patients benefit from future medical innovations.
“We know through our experience with the Lyrica situation that the absence of any national policy or framework for second medical use patents in the UK has been a cause of concern and confusion for many, including us,” says Phillips. “This was reflected on by the judge who has highlighted the need for a national-level solution for second medical use patent situations of this nature that may arise at present and in the future.”

Citation: The Pharmaceutical JournalURI: 20069353

domingo, 13 de setembro de 2015

Top 5 Medical Technology Innovations

Against the backdrop of health care reform and a controversial medical device tax, medical technology companies are focusing more than ever on products that deliver cheaper, faster, more efficient patient care. They are also making inroads with U.S. Food & Drug Administration regulators to re-engineer the complex review and approval process for new medical devices.
Many in the industry have long felt overly burdened by what they consider to be an unnecessarily complex approval process. Critics claim it impedes innovation and delays the availability of better health care. To change that perception, the FDA last year announced a new Medical Device Innovation Consortium (MDIC) charged with simplifying the process of designing and testing new technologies. With input from industry, government, and other nonprofit organizations, public-private MDIC will prioritize the regulatory science needs of the medical device community and fund projects to streamline the process.
"By sharing and leveraging resources, MDIC may help industry to be better equipped to bring safe and effective medical devices to market more quickly and at a lower cost," says Jeffrey Shuren, M.D., J.D., director of the FDA's Center for Devices and Radiological Health.
As the regulators, politicians, and corporate executives hash out these details, industry engineers and scientists continue to push through new ideas for improving and managing human health. Every year, industry observers like the Cleveland Clinic and the medical device trade press single out their favorite technology trends. These thought leaders agree that today's best technologies strike a balance between reducing the overall cost of medical care and increasing safety and survival rates—and isn't that what health care reform is all about?
Here are five emerging technologies to watch in the year ahead.
The MelaFind optical scanner from MELA Sciences. Image: MelaFind.com

1. Cutting Back on Melanoma Biopsies

With the most deadly form of skin cancer, melanoma, a huge number of dangerous-looking moles are actually harmless, but has always been impossible to know for sure without an invasive surgical biopsy. Today dermatologists have new help in making the right call — a handheld tool approved by the FDA for multispectral analysis of tissue morphology. The MelaFind optical scanner is not for definitive diagnosis but rather to provide additional information a doctor can use in determining whether or not to order a biopsy. The goal is to reduce the number of patients left with unnecessary biopsy scars, with the added benefit of eliminating the cost of unnecessary procedures. TheMelaFind technology (MELA Sciences, Irvington, NY) uses missile navigation technologies originally paid for the Department of Defense to optically scan the surface of a suspicious lesion at 10 electromagnetic wavelengths. The collected signals are processed using heavy-duty algorithms and matched against a registry of 10,000 digital images of melanoma and skin disease.
The ATI Neurostimulator from Autonomic Technologies. Image: ATI-SPG.com

2. Electronic Aspirin

For people who suffer from migraines, cluster headaches, and other causes of chronic, excruciating head or facial pain, the "take two aspirins and call me in the morning" method is useless. Doctors have long associated the most severe, chronic forms of headache with the sphenopalatine ganglion (SPG), a facial nerve bundle, but haven't yet found a treatment that works on the SPG long-term. A technology under clinical investigation at Autonomic Technologies, Inc., (Redwood City, CA) is a patient-powered tool for blocking SPG signals at the first sign of a headache. The system involves the permanent implant of a small nerve stimulating device in the upper gum on the side of the head normally affected by headache. The lead tip of the implant connects with the SPG bundle, and when a patient senses the onset of a headache, he or she places a handheld remote controller on the cheek nearest the implant. The resulting signals stimulate the SPG nerves and block the pain-causing neurotransmitters.
The Symphony tCGM biosensor from Echo Therapeutics. Image: EchoTX.com

3. Needle-Free Diabetes Care

Diabetes self-care is a pain—literally. It brings the constant need to draw blood for glucose testing, the need for daily insulin shots and the heightened risk of infection from all that poking. Continuous glucose monitors and insulin pumps are today's best options for automating most of the complicated daily process of blood sugar management – but they don't completely remove the need for skin pricks and shots. But there's new skin in this game. Echo Therapeutics (Philadelphia, PA) is developing technologies that would replace the poke with a patch. The company is working on a transdermal biosensor that reads blood analytes through the skin without drawing blood. The technology involves a handheld electric-toothbrush-like device that removes just enough top-layer skin cells to put the patient's blood chemistry within signal range of a patch-borne biosensor. The sensor collects one reading per minute and sends the data wirelessly to a remote monitor, triggering audible alarms when levels go out of the patient's optimal range and tracking glucose levels over time.
The Telemedicine System from InTouch Technologies. Image: InTouchHealth.com

4. Robotic Check-Ups

A pillar of health reform is improving access to the best health care for more people. Technology is a cost-effective and increasingly potent means to connect clinics in the vast and medically underserved rural regions of the United States with big city medical centers and their specialists. Telemedicine is well established as a tool for triage and assessment in emergencies, but new medical robotsgo one step further—they can now patrol hospital hallways on more routine rounds, checking on patients in different rooms and managing their individual charts and vital signs without direct human intervention. The RP-VITA Remote Presence Robot produced jointly by iRobot Corp. and InTouch Health is the first such autonomous navigation remote-presence robot to receive FDA clearance for hospital use. The device is a mobile cart with a two-way video screen and medical monitoring equipment, programmed to maneuver through the busy halls of a hospital.
The Sapien transcatheter aortic valve from Edwards Lifesciences. Image: Edwards.com

5. A Valve Job with Heart

The Sapien transcatheter aortic valve is a life-saving alternative to open-heart surgery for patients who need new a new valve but can't endure the rigors of the operation. Manufactured byEdwards Life Sciences (Irvine, CA), theSapien has been available in Europe for some time but is only now finding its first use in U.S. heart centers—where it is limited only to the frailest patients thus far. The Sapien valve is guided through the femoral artery by catheter from a small incision near the grown or rib cage. The valve material is made of bovine tissue attached to a stainless-steel stent, which is expanded by inflating a small balloon when correctly placed in the valve space. A simpler procedure that promises dramatically shorter hospitalizations is bound to have a positive effect on the cost of care.